相关实验视频
Updated: May 27, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.2K
在帕金森病中使用deferiprone的治疗方式:SKY和EMBARK研究
David Devos1, Olivier Rascol2, Wassilios G Meissner3,4
1Department of Medical Pharmacology, Department of Neurology, Expert Center of Parkinson's Disease, Université de Lille, Lille, Lille Neuroscience and Cognition INSERM 1172, France.
Journal of Parkinson's disease
|February 20, 2025
概括
当与L-dopa结合使用时,德费里在早期帕金森病 (PD) 患者的运动功能没有显著改善. 以前没有接受过治疗的患者在没有L-dopa的情况下经历了症状恶化.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 尼格罗斯特里亚特通路中的铁过载与帕金森病 (PD) 模型中的神经元损失有关.
- 德费里是一种铁化剂,在PD中具有潜在的治疗应用.
研究的目的:
- 评估deferiprone在减缓早期PD患者运动残疾进展方面的安全性和有效性.
- 评估多巴胺激素治疗和以前未经治疗的患者群体中的德费里的作用.
主要方法:
- 两个II期多中心研究 (SKY和EMBARK) 纳入了早期PD患者 (从查开始<3年).
- SKY随机选择了接受安慰剂或德利 (300-1200毫克两次一天) 的多巴胺治疗的患者.
- 在EMBARK治疗的患者 (多巴胺激素治疗或未经治疗的) 中,使用了deferiprone (15 mg/kg两次).
- 主要结局是运动障碍学会统一帕金森病评分表 (MDS-UPDRS) 第三部分运动评分从基线到9个月的变化.
主要成果:
- 在SKY中,大多数德利剂量显示了与安慰剂相似的运动功能的恶化;600毫克剂量有非显著的改善趋势.
- 在EMBARK中,多巴胺治疗的患者在MDS-UPDRS Part III中发生了无意义的变化,而未经治疗的患者显示出明显的恶化.
- 可能与deferiprone相关的不良事件发生在35.7%-88.9%的参与者中.
结论:
- 德费里,当添加到L-dopa时,在早期PD中没有显示出显著的运动功能的好处.
- 在没有L-dopa的情况下接受deferiprone治疗的先前治疗的患者经历了症状恶化,这凸显了多巴胺疗法的重要性.
相关概念视频
Parkinson's Disease: Treatment
187
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
187
Parkinson's Disease: Overview
429
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
429
Direct-Acting Cholinergic Agonists: Therapeutic Uses
672
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
672
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
242
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
242
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
127
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
127
Drug Therapy
35
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
35

